Vanda Pharmaceuticals (VNDA) Raw Materials (2014 - 2015)
Vanda Pharmaceuticals (VNDA) reported Raw Materials of $128000.0 for Q3 2015, down 39.91% on a YoY basis from $213000.0 in Q3 2014, and little changed sequentially from $128000.0 in Q2 2015.
Vanda Pharmaceuticals (VNDA) Raw Materials (2014 - 2015) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 2 years of Raw Materials data on file, last reported at $128000.0 in Q3 2015.
- For the quarter ending Q3 2015, Raw Materials fell 39.91% year-over-year to $128000.0; the trailing twelve-month figure through Sep 2015 stood at $128000.0 (down 39.91% YoY), and the FY2014 full-year result was $198000.0, changed N/A from the prior year.
- Raw Materials steadied at $128000.0 in Q3 2015, from $128000.0 in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $213000.0 in Q3 2014 to a low of $128000.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 128,000.00 |
| Jun 30, 2015 | 128,000.00 |
| Mar 31, 2015 | 162,000.00 |
| Dec 31, 2014 | 198,000.00 |
| Sep 30, 2014 | 213,000.00 |
| Jun 30, 2014 | 145,000.00 |
| Mar 31, 2014 | 143,000.00 |